Survival analysis of patients with rheumatic MS after PBMV compared with MVS in a low-to-middle-income country

A. M. Ambari · B. Setianto · A. Santoso · B. Dwiputra · B. Radi · A. A. Alkatiri · A. B. Adji · E. Susilowati · F. Tulrahmi · M. J. M. Cramer · P. A. Doevendans

Published online: 29 July 2019
© The Author(s) 2019

Abstract

Introduction Rheumatic mitral stenosis continues to be prevalent in developing countries, notably in endemic areas. Over the last few decades, percutaneous balloon mitral valvuloplasty (PBMV) has been established as a lower-cost alternative treatment for mitral stenosis (MS) in low-to-middle-income countries. PBMV has also been suggested to be an effective and safe alternative treatment modality. This study aims to analyse the survival of rheumatic MS patients treated with PBMV compared with those treated with mitral valve surgery (MVS).

Methods This study was a national, single-centre, longitudinal study using a survival analysis method in 329 consecutive patients suffering from rheumatic heart disease with severe MS who underwent PBMV compared with 142 consecutive patients with similar characteristics who underwent MVS between January 2011 and December 2016. Survival analysis and event-free duration were determined over a median follow-up of 24 months in the PBMV group and 27 months in the MVS group.

Results The results showed that of the 329 consecutive patients in the PBMV group, 61 patients (18.5) had an event (6 patients died and 55 patients were hospitalized), and of the 142 consecutive patients in the MVS group, 19 patients (13.4%) had an event (5 patients died, and 14 patients were hospitalized). The hazard ratio was 0.631 (95% confidence interval, 0.376–1.058; \( P = 0.081 \)). Longer short-term survival was found in the MVS group but was not statistically significant. Event-free survival was significantly longer in the MVS group \( (P = 0.002) \), by 5 months.

Conclusions In this study, the efficacy and safety of PBMV was reconfirmed, as PBMV proved to be non-inferior to MVS in survival prognosis, but sustained event-free duration was significantly better in the MVS group than in the PBMV group.

Keywords Rheumatic mitral stenosis · Percutaneous balloon mitral valvulotomy · Mitral valve surgery · Survival analysis

What's new

- Percutaneous balloon mitral valvuloplasty is non-inferior compared with mitral valve surgery in prognostics for survival, but sustained event-free duration was significantly better in the mitral valve surgery group.
- Higher event-free survival was found in the mitral valve surgery group, but it was not statistically significant.
- Event-free duration was significantly 5 months longer in the mitral valve surgery group \( (P = 0.002) \).
Introduction

Rheumatic heart disease (RHD) is a major burden in developing countries and causes most cardiovascular morbidity and mortality in children and young adults. The worldwide prevalence and annual incidence of RHD have been approximated to be >15 million cases and >280,000 cases per year, respectively. Recent studies in Asia have estimated an existing RHD burden of 10.8–15.9 million patients, accounting for 356,000–524,000 deaths per year [1]. RHD is a progressive and chronic condition caused by complement-mediated damage to the atrioventricular valves, frequently including mitral stenosis, that occurs as a result of the inflammatory response in rheumatic fever [2].

The safety and efficacy of percutaneous balloon mitral valvuloplasty (PBMV) and mitral valve surgery (MVS) have already been established. PBMV is a safe and well-tolerated intervention and is associated with short-term benefits [3]. The increasing burden to reduce health-related expenses makes it compulsory to provide an effective and safe yet economical intervention. Over the last few decades, PBMV has been established as a lower-cost alternative to MVS in low-to-middle-income countries [4–7]. This study was conducted to identify in-hospital survival and short-term survival of rheumatic mitral stenosis patients undergoing PBMV compared with those undergoing MVS.

Methods

Patient Selection

We conducted a single-centre, retrospective follow-up study. All 471 consecutive patients admitted with severe mitral stenosis with or without tricuspid valve repair or replacement between January 2011 and December 2016 were included. The study group comprised 329 patients who underwent PBMV and 142 patients who underwent MVS. Patients with congenital heart disease or those who received non-mitral valve surgery or coronary artery bypass grafting were excluded from this study. The data were acquired from medical records and local databases.

Treatment Strategy

The definite treatment strategy for patients with severe MS, either PBMV or MVS, was determined during the pre-surgery conference attended by cardiologists and surgeons and was based on echocardiographic data, patient age, and comorbidities. Our institutional review board approved the retrospective analysis of the clinical data of these subjects.

Treatment indications followed the ESC guidelines for intervention in MS. PBMV was indicated in symptomatic patients with a valve area <1.5 cm² if symptoms could not be explained by another cause, and if the anatomy was favourable, in symptomatic patients with a contraindication or a high risk for surgery, as well as in asymptomatic patients without unfavourable clinical or anatomical characteristics for PBMV with high thromboembolic risk and/or a high risk of haemodynamic decompensation. PBMV was contraindicated if the mitral valve area >1.5 cm², if there was a presence of left atrial thrombus, if a patient had more than mild mitral regurgitation, in the case of severe or bi-commisural calcification, in the case of an absence of the commissural fusion, in patients with severe concomitant aortic valve disease or severe combined tricuspid stenosis, if a patient had regurgitation that required surgery, and in patients with concomitant coronary artery disease that required bypass surgery. Mitral valve surgery is indicated in symptomatic patients who are not suitable for PBMV [8]. The Wilkins score was calculated. A mitral valve with a score less than 8 indicated that the patient was a candidate for PBMV. In patients with a score ≥8, especially in those with more than moderate mitral regurgitation, surgical therapy was performed, except in patients with serious comorbidities [9].

Treatment Technique

Percutaneous balloon mitral valvuloplasty procedures were performed by a percutaneous trans-septal anterograde approach and the Inoue balloon technique, according to the stepwise technique procedure, under echocardiographic guidance. The mitral valve area was calculated using the Gorlin formula [10]. MVS was performed with mitral valve replacement or mitral valve repair. Mitral valve replacement was conducted in 115 of 142 patients (81%), and mitral valve repair was conducted in 27 of 142 patients (19%).

Measurement

The diagnosis of rheumatic mitral valve disease was made by echocardiography. Echocardiography was performed and analysed in the same centre. Rheumatic valve diseases were diagnosed using the World Heart Federation Criteria for Rheumatic Heart Disease. Comprehensive 2-dimensional and colour Doppler echocardiographic evaluation was performed in all patients before PBMV or MVS. In addition to routine measurements of cardiac chamber dimensions and ejection fraction by the modified Simpson method, the mitral gradient and the peak pressure gradient of tricuspid regurgitation were calculated. The morphological features of the mitral valve were categorised as previously described, and the total echocardiographic score was obtained by adding the scores of each of the following individual morphological features: leaflet mobility, thickness, calcification, and subvalvular lesions. The mitral valve area was measured by direct planimetry to calculate the mitral...
Hazard Ratio: 0.631 (95% CI: 0.376–1.058)  
\(P\)-value = 0.081

Mean of event-free duration:  
PBMV = 60.7 months  
MVS = 65.8 months  
\(P\)-value = 0.002

gradient and the peak pressure gradient of tricuspid regurgitation.

**Follow-up**

Follow-up data were collected from January until June 2017. The data were obtained either from medical records during patient visits to the outpatient clinic or during hospitalisation or by telephone interviews. The endpoints were defined as the clinical events of cardiovascular death and hospitalisation.

**Data Analysis**

Categorical variables are presented as numbers and percentages and were compared by \(\chi^2\) or Fisher’s exact test. Continuous variables and actuarial survival rates are expressed as the mean standard deviation and were compared by unpaired \(t\)-tests, except for follow-up duration, which is expressed as a median. The Cox proportional hazards model was used to determine whether the event-free survival differed significantly between PBMV and MVS patients after controlling for the differences in their pre-procedural risk profiles. Bivariate analysis was performed with a Cox model to determine the risk factors of an outcome. Variables were entered in a Cox multivariate model with a backward selection procedure and a significance level of \(P<0.05\) to prevent failure in identifying variables known to be important [11]. Two-way interactions were studied between these selected variables with a stratified log-rank test. The final Cox multivariate model was established by a backward selection of these variables with a significance level of \(P<0.05\). Cumulative survival curves were determined according to the Kaplan-Meier method (Fig. 1). The analysis was performed with SPSS.

**Results**

**Baseline Characteristics and short-term Outcomes**

This study involved a total of 471 patients, comprising 329 PBMV patients and 142 MVS patients. From 142 patients who underwent MVS, mitral valve repair was performed in 26 patients (18.3%) with mitral valve replacement in 116 patients (81.7%). The median follow-up was 24 months in the PBMV group and 27 months in the MVS group. The endpoints of the present study were the frequency of objective clinical events, including cardiovascular death and hosp-

**Table 1** Frequency distribution of patient characteristics in the PBMV and MVS groups

| Variable                  | PBMV \((n=329)\) | MVS \((n=142)\) |
|---------------------------|------------------|----------------|
| Age, y                    | 39.3 ± 1.6       | 41.2 ± 11.3    |
| Male, n (%)               | 87 (26.4%)       | 57 (4.1%)      |
| Smokers, n (%)            | 35 (10.6%)       | 28 (19.7%)     |
| Diabetes mellitus, n (%)  | 6 (1.8%)         | 9 (6.3%)       |
| Hypertension, n (%)       | 29 (8.8%)        | 13 (9.2%)      |
| Dyslipidaemia, n (%)      | 3 (0.9%)         | 10 (7%)        |
| Anticoagulant, n (%)      | 226 (66.8%)      | 142 (100%)     |
| ACE inhibitor, n (%)      | 1 (0.3%)         | 86 (60.6%)     |
| Beta blocker, n (%)       | 149 (45.3%)      | 68 (47.9%)     |
| Digitalis, n (%)          | 146 (44.4%)      | 35 (24.6%)     |
| Diuretic, n (%)           | 291 (88.4%)      | 87 (61.3%)     |
| AF, n (%)                 | 200 (60.8%)      | 83 (58.5%)     |
| BMI, n (%)                |                  |                |
| – Underweight             | 68 (20.7%)       | 46 (33.3%)     |
| – Normal                  | 136 (41.3%)      | 58 (42%)       |
| – Overweight              | 57 (17.3%)       | 12 (8.7%)      |
| – Obesity                 | 68 (20.7%)       | 22 (15.9%)     |
| Wilkins score Median score | 7                | 8              |

**Table 2** Frequency distribution of events in the PBMV and MVS groups

| Variable                        | PBMV \((n=329)\) | MVS \((n=142)\) |
|---------------------------------|------------------|----------------|
| Event (mortality/morbidity), n (%) | 61 (18.5%) | 19 (13.4%)  |
| Mortality, n                    | 6                | 5              |
| Rehospitalisation, n            | 55               | 14             |
| – Congestive heart failure, n   | 49               | 13             |
| – Repeat intervention, n        | 2                | 0              |
| – Arrhythmia                    | 3                | 0              |
| – Cerebrovascular accident, n   | 1                | 1              |

PBMV percutaneous balloon mitral valvuloplasty, MVS mitral valve surgery, ACE angiotensin-converting enzyme, AF atrial fibrillation, BMI body mass index
Table 3  Bivariate analysis predictors of event outcomes

| Variable          | PBMV (n=329) | MVS (n=142) |
|-------------------|--------------|-------------|
|                   | n            | HR (95% CI) | P-value | n            | HR (95% CI) | P-value |
| Male              | 16 (18.4%)   | 1.0 (0.6–1.8) | 0.977   | 8 (14%)      | 1.1 (0.4–2.7) | 0.894   |
| Age               | Mean 39.3±1.6 | 1.0 (0.9–1.0) | 0.593   | Mean 41.2±11.3 | 1.0 (0.9–1.1) | 0.194   |
| Wilkins score     | Median 7     | 1.1 (0.9–1.4) | 0.485   | Median 8     | 1.2 (0.7–1.1) | 0.555   |
| Smokers           | 6 (17.1%)    | 0.9 (0.4–2.3) | 0.957   | 4 (14.3%)    | 1.0 (0.3–3.1) | 0.979   |
| DM                | 1 (16.7%)    | 0.8 (0.1–5.7) | 0.812   | 0               | –             | 0.456   |
| Hypertension      | 8 (27.6%)    | 1.6 (0.8–3.4) | 0.222   | 2 (15.4%)    | 1.3 (0.3–5.9) | 0.692   |
| Dyslipidaemia     | 1 (33.3%)    | 3.1 (0.4–22.4) | 0.625   | 0               | –             | 0.434   |
| Anticoagulant     | 45 (19.9%)   | 1.3 (0.7–2.3) | 0.404   | 19 (13.4%)   | –             | –       |
| ACE inhibitor     | 1 (100%)     | 9.3 (1.3–67.7) | 0.028   | 11 (12.8%)   | 0.9 (0.4–2.5) | 0.954   |
| Beta blocker      | 26 (17.4%)   | 0.9 (0.6–1.5) | 0.743   | 10 (14.7%)   | 1.1 (0.5–2.8) | 0.807   |
| Digitalis         | 27 (18.5%)   | 0.9 (0.5–1.4) | 0.588   | 3 (8.6%)     | 0.5 (0.1–1.7) | 0.254   |
| Diuretic          | 56 (19.2%)   | 1.6 (0.6–4.0) | 0.313   | 10 (11.5%)   | 0.6 (0.2–1.4) | 0.239   |
| ECG (AF)          | 42 (21%)     | 1.5 (0.8–2.5) | 0.173   | 10 (12%)     | 0.8 (0.3–1.9) | 0.604   |
| BMI:              |              |              |         |              |              |         |
| – Underweight     | 13 (19.1%)   | 1.0          |         | 5 (10.9%)    | 1.0          |         |
| – Normal          | 24 (17.6%)   | 0.9 (0.5–1.9) | 0.944   | 6 (10.3%)    | 1.0 (0.3–3.3) | 0.995   |
| – Overweight      | 9 (15.8%)    | 0.8 (0.3–1.9) | 0.643   | 1 (8.3%)     | 0.8 (0.1–6.9) | 0.845   |
| – Obesity         | 15 (22.1%)   | 1.1 (0.5–2.3) | 0.791   | 6 (27.3%)    | 3.3 (0.9–10.9) | 0.055   |

PBMV=percutaneous balloon mitral valvuloplasty, MVS=mitral valve surgery, HR=hazard ratio, CI=confidence interval, DM=diabetes mellitus, ACE=angiotensin-converting enzyme, ECG=electrocardiography, AF=atrial fibrillation, BMI=body mass index

Table 4  Multivariate analysis predictors of event outcomes

| Variable       | HR  | 95% CI       | P-value |
|----------------|-----|--------------|---------|
| Treatment      | 0.6 | 0.3–1.1      | 0.081   |
| Wilkins score  | 1.1 | 0.9–1.4      | 0.303   |
| Digitalis      | 0.7 | 0.4–1.1      | 1.124   |
| Diuretic use   | 1.2 | 0.6–2.4      | 0.648   |

The main finding of this study is that there were no significant differences in survival prognosis between groups. Short-term survival was similar in both groups, and the hazard ratio for the clinical events after MVS compared with PBMV was 0.631 (95% confidence interval [CI], 0.376–1.058; P=0.081). Sustained life expectancy was found in the MVS group compared with the PBMV group. The event-free duration was significantly longer in the MVS group (P=0.002), by 5 months.

The patient characteristics that were assessed in this study were sex, age, body mass index (BMI), smoking status, diabetes mellitus (DM), hypertension, dyslipidaemia, anticoagulant (warfarin) use, angiotensin-converting enzyme inhibitor use, beta blocker use, digitalis use, diuretic use and the presence of atrial fibrillation. These variables did not interfere with the survival results, because the bivariate analysis showed that none of them was significantly correlated with the outcome events. This result was in accordance with that of Song et al. (2010), who identified the long-term outcomes between PBMV and
MVS in a total of 561 consecutive patients between January 1995 and December 2000, with a median follow-up of 109 months. The previous study showed that 20 patients (13%) who underwent MVS died, and 78 patients (19%) who underwent PBMV died. Based on the unadjusted survival results, both groups had the same event-free survival rate (HR = 1.51; 95% CI: 0.914–2.496; \( P = 0.1079 \)). After the data were adjusted for age, left atrial anteroposterior diameter, and echo findings, the hazard ratio became 3.729 (95% CI: 1.962–7.082; \( P \)-value <0.001). The results led to the conclusion that patients who receive MVS have better longer-term survival rates than those who receive PBMV [12].

The results of research conducted by Chen et al. (2015) indicated that PBMV is a safe and effective procedure for RHD patients with MS and tricuspid regurgitation. This procedure can relieve symptoms, reduce the magnitude of tricuspid regurgitation and can improve the quality of life and patient prognosis, but the long-term effects need to be monitored. In this study, the tricuspid regurgitation area (TRA) increased when the mitral valve area (MVA) decreased, and there was a reverse relationship between the two (\( r = -0.8 \), \( t = 27.115 \), \( P < 0.01 \)). In particular, tricuspid regurgitation contributes to increased morbidity and mortality despite surgical and percutaneous measures of mitral valve disease [13]. Kim et al. (2007) compared long-term outcomes after mitral valve replacement or repeated PBMV in patients with restenosis after a previous balloon valvotomy. In a survival analysis until 40 months postoperatively, both procedures had the same event-free survival, but 6 years and 9 years of follow-up showed that mitral valve replacement had significantly longer event-free survival than repeated PBMV [10]. Additionally, a study by Lee et al. (2015) aimed to determine the outcomes of mitral valve repair in patients with mitral stenosis after PBMV [14]. The results showed that the mean valve area using planimetry increased (1.16–1.62; \( P = 0.0001 \)), the pressure half time using Doppler ultrasound decreased (202.4–152; \( P = 0.0001 \)), and the mean pressure gradient using Doppler ultrasound decreased (9.4–5.8; \( P = 0.0021 \)).

Based on these results, mitral valve repair can be suggested as an alternative method for patients with mitral restenosis who have received PBMV [14–19]. Song et al. (2010) found that patients with abnormal echocardiography findings and high atrial fibrillation rhythm showed better outcomes after MVS. This statement was confirmed by other studies [20–25], showing that MVS has advantages over PBMV because, in cases of the combination of MS with tricuspid regurgitation and atrial fibrillation rhythm, MVS is the best choice for treatment, but our study calculated atrial fibrillation rhythm as a possible confounding factor and found that it was not statistically significant to this research.

**Limitations**

This study was a single-centre study using an observational study design with inherent limitations. Different follow-up times were unavoidable, but the median time follow-up in this study showed no significant differences between the groups. This study is too limited by the short follow-up period to determine survival in the PBMV and MVS groups. A longer time to follow-up and a larger sample size may have led to more reliable results.

**Conclusions**

In this retrospective, observational single-centre study, the short-term safety and efficacy of PBMV was reconfirmed, as PBMV proved to be non-inferior to MVS in survival prognosis, but the sustained survival duration was significantly better in the MVS group.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Rodriguez-Fernandez R, Amiya R, Wyber R, et al. Rheumatic heart disease among adults in a mining community of Papua, Indonesia: findings from an occupational cohort. HeartAsia. 2015;7:44–8.
2. Lu L, Hong L, Fang J, et al. Effectiveness of Percutaneous balloon mitral Valvuloplasty for rheumatic mitral Stenosis with mild to severe mitral regurgitation. Biomed Res Int. 2016;2016:1–4.
3. Jorge E, Pan M, Baptista R, et al. Predictors of very late events after Percutaneous mitral Valvuloplasty in patients with mitral Stenosis. Am J Cardiol. 2016;117:1978–84.
4. Becker G, Benenati J, Zemel G, et al. Percutaneous placement of a balloon-expandable Intraluminal graft for life-threatening Subclavian arterial hemorrhage. J Vasc Interv Radiol. 1991;2:225–9.
5. Hoedemaker G, la Rivière AV, David GK, et al. Percutaneous transluminal balloon valvuloplasty of the aortic valve in 15 patients. Ned Tijdschr Geneeskd. 1987;131:1265–9.
6. Vahanian A, Cormier B, Michel PL, et al. Percutaneous mitral commissurotomy. Presse Med. 1992;21:857–64.
7. Babic UU, Dorros G, Pejic P, et al. Percutaneous mitral Valvuloplasty: retrograde, transarterial double-balloon technique utilizing the transseptal approach. Catheter Cardiovasc Interv. 1988;14:229–37.
8. Baumgartner H, Falk V, Bax J, et al. ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739–91.
9. Nobuyoshi M, Arita T, Shirai S, et al. Percutaneous balloon mitral valvuloplasty. Circulation. 2009;119:211–9.
10. Kim J, Ha J, Kim J, et al. Comparison of long-term outcome after mitral valve replacement or repeated balloon mitral Valvotomy in patients with Restenosis after previous balloon Valvotomy. Am J Cardiol. 2007;99:1571–4.
11. Bursac Z, Gauss C, Williams D, et al. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3:17.
12. Song J, Kim M, Yun S, et al. Long-term outcomes of percutaneous mitral balloon valvuloplasty versus open cardiac surgery. J Thorac Cardiovasc Surg. 2010;139:103–10.
13. Chen Z, Hong L, Wang H, et al. Application of Percutaneous balloon mitral Valvuloplasty in patients of rheumatic heart disease mitral Stenosis combined with tricuspid regurgitation. Chin Med J. 2013;128:1478–82.
14. Lee S, Chee H, Kim J, et al. Postoperative outcomes of mitral valve repair for mitral Restenosis after Percutaneous balloon mitral Valvotomy. Korean J Thorac Cardiovasc Surg. 2015;48:328–34.
15. El Oumeiri B, Boodhwani M, Glineur D, et al. Extending the scope of mitral valve repair in rheumatic disease. Ann Thorac Surg. 2009;87:1735–40.
16. Omeroglu SN, Kirali K, Mansuroglu D, et al. Is posterior leaflet extension and associated Commissurotomy effective in rheumatic mitral valve disease? Long-term outcome. Tex Heart Inst J. 2004;31:240–5.
17. Bakir I, Onan B, Onan IS, et al. Is rheumatic mitral valve repair still a feasible alternative? Indications, technique, and results. Tex Heart Inst J. 2013;40:163–9.
18. Chan PG, Hayanga AJ, Badhwar V. Repair of rheumatic mitral Stenosis with Bicommissural release, anterior leaflet augmentation and oversized Annuloplasty. Multimed Man Cardiothorac Surg. 2014;20:14–20.
19. Kim J, Kim H, Moon D, et al. Long-term outcomes after surgery for rheumatic mitral valve disease: valve repair versus mechanical valve replacement. Eur J Cardiothorac Surg. 2010;37:1039–46.
20. King RM, Schaff HV, Danielson GK, et al. Surgery for tricuspid regurgitation late after mitral valve replacement. Circulation. 1984;70:193–7.
21. Matsuyama K, Matsumoto M, Sugito T, et al. Predictors of residual tricuspid regurgitation after mitral valve surgery. Ann Thorac Surg. 2003;75:1826–8.
22. Mc Carthy P, Bhudia S, Rajeswaran J, et al. Tricuspid valve repair: durability and risk factors for failure. J Thorac Cardiovasc Surg. 2004;127:674–85.
23. Kim HK, Kim YJ, Kim KI, et al. Impact of the Maze operation combined with left-sided valve surgery on the change in tricuspid regurgitation over time. Circulation. 2005;112:14–9.
24. Stulak JM, Schaff HV, Dearani JA, et al. Restoration of sinus rhythm by the Maze procedure halts progression of tricuspid regurgitation after mitral surgery. Ann Thorac Surg. 2008;86:40–4.
25. Je H, Song H, Jung S, et al. Impact of the Maze Operation on the Progression of Mild Functional Tricuspid Regurgitation. J Thorac Cardiovasc Surg. 2008;136:1187–92.